OmniAb, Inc. (OABIW)
- Previous Close
0.3300 - Open
0.3300 - Bid --
- Ask --
- Day's Range
0.3300 - 0.3300 - 52 Week Range
0.3300 - 0.3300 - Volume
24,952 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
www.omniab.comRecent News: OABIW
View MoreCompare To: OABIW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OABIW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-287.29%
Return on Assets (ttm)
-13.95%
Return on Equity (ttm)
-19.87%
Revenue (ttm)
21.71M
Net Income Avi to Common (ttm)
-62.38M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
57.23M
Total Debt/Equity (mrq)
8.27%
Levered Free Cash Flow (ttm)
-17.42M
Company Insights: OABIW
OABIW does not have Company Insights